GSK Moves for New Trial in Paxil Suicide Action Following $3 Million Verdict

CHICAGO — GlaxoSmithKline has moved for a new trial in a Paxil suicide case following a jury’s award of $3 million to the plaintiff, arguing that the learned intermediary doctrine bars the failure-to-warn claim because the prescribing doctor admitted he was aware of the drug’s risks before he prescribed the drug to the decedent.

In a May 25 motion filed in the U.S. District Court for the Eastern District of Illinois, GSK further maintained that the plaintiff failed to prove that the 2010 Paxil labeling was inadequate, that the drug’s generic equivalent, paroxetine, can cause suicidal thoughts or behavior in …